

GLAXOSMITHKLINE PLC  
Form 6-K  
January 13, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 13 January 2017

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Andrew Witty
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.7338	43
n/a (single transaction)	
  - d) Aggregated information  
Aggregated volume Price
  - e) Date of the transaction 2017-01-12
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status CEO Designate
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

- |  |   |
|--|---|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')  |
| b) Nature of the transaction               | ISIN: GB0009252882<br>Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan. |
| c) Price(s) and volume(s)                  | Price(s)      Volume(s)<br>£15.7338      12   |
| d) Aggregated information                  | n/a (single transaction)  |
| e) Date of the transaction                 | 2017-01-12  |
| f) Place of the transaction                | London Stock Exchange (XLON)  |

1. Details of PDMR/person closely associated with them ('PCA')

- |                                    |  |
|------------------------------------|--|
| a) Name                            | Mr R G Connor                            |
| b) Position/status                 | President, Global Manufacturing & Supply |
| c) Initial notification/ amendment | Initial notification                     |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |  |   |
|--|---|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')  |
| b) Nature of the transaction               | ISIN: GB0009252882<br>Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan. |
| c) Price(s) and volume(s)                  | Price(s)      Volume(s)<br>£15.7338      51   |
| d) Aggregated information                  | n/a (single transaction)  |

Aggregated volume Price

- |    |                          |                                 |
|----|--------------------------|---------------------------------|
| e) | Date of the transaction  | 2017-01-12                      |
| f) | Place of the transaction | London Stock Exchange<br>(XLON) |
- 
1. Details of PDMR/person closely associated with them ('PCA')
 

a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
  2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
  3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b)	Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.
c)	Price(s) and volume(s)	Price(s)      Volume(s) £15.7338      16
d)	Aggregated information	n/a (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	London Stock Exchange (XLON)
  1. Details of PDMR/person closely associated with them ('PCA')
 

a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics & Compliance
c)	Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

b) Nature of the transaction  
 ISIN: GB0009252882  
 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £15.7338 16  
 n/a (single transaction)

d) Aggregated information  
 Aggregated volume Price

e) Date of the transaction 2017-01-12  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain  
 b) Position/status President, Global Pharmaceuticals

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

b) Nature of the transaction  
 ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.7338	11
	n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction	2017-01-12
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
--	--

ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.
------------------------------	---

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.7338	59
d) Aggregated information	n/a (single transaction)	

Aggregated volume Price

- e) Date of the transaction 2017-01-12  
 f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Ms C Thomas  
 b) Position/status SVP, Human Resources  
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
 a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted  
 a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882  
 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.
- b) Nature of the transaction
- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £15.7338 59  
 n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2017-01-12  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Mr P C Thomson  
 b) Position/status

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

SVP, Communications &  
Government Affairs

- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882  
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s)                 | Volume(s) |
|--------------------------|-----------|
| £15.7338                 | 32        |
| n/a (single transaction) |           |
- d) Aggregated information  
Aggregated volume Price
- e) Date of the transaction 2017-01-12  
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr P J T Vallance  
b) Position/status President, R&D
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')



ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 12  
 January 2017, on shares held  
 through the Company's  
 ShareReward Plan.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7338	35
n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs V A Whyte

b) Position/status Company Secretary

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 12  
 January 2017, on shares held  
 through the Company's  
 ShareReward Plan.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7338	41
n/a (single transaction)	

d) Aggregated information

Aggregated volume Price

e) Date of the transaction	2017-01-12
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 13, 2017

By: VICTORIA WHYTE-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc